Diabetic patients after kidney transplant
Conditions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female aged 20 years or over, under 70 years old at the time of agreement acquisition 2. Patients diagnosed with diabetes 3. Patients who have undergone renal transplant 4. Patients with HbA1c (NGSP) of 6.0% or more and 9.0% or less Patients with Estimated Glomerular Filtration Rate (eGFR) of 30 mL / min / 1.73 m ^ 2 or more 5. Patients judged to have indications to use SGLT 2 inhibitors under normal medical treatment 6. Patients who have not used other SGLT2 inhibitors prior to the initiation of SGLT2 inhibitor prescription
Exclusion criteria
Exclusion criteria: 1. Patients with a history of hypersensitivity to components of SGLT2 inhibitors 2. Type 1 diabetes 3. Patients with postoperative ureteral stenosis such as ureteral stent placement 4. Patients with a history of repeated pyelonephritis 5. Patients with severe ketosis or diabetic coma 6. Patients with severe infections, before and after surgery, severe trauma 7. Patients with end-stage renal failure who are undergoing hemodialysis or peritoneal dialysis 8. Pregnant women or patients with potential pregnancy 9. Patients who research managers judged inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c (NGSP value), glycoalbumin, blood glucose before and after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change before and after treatment of the following items; Urinary protein, urinary albumin and renal function (estimated glomerular filtration rate; eGFR) 2. Safety Event of the following side effects; Low blood sugar Urinary Tract Infections and Genital Infections Diabetic ketoacidosis Renal dysfunction Liver dysfunction fracture Malignant tumor Cardiac and cerebrovascular events Skin symptoms | — |
Countries
Japan
Contacts
Tokyo Women's Medical University School of Medicine Diabetes Center